Nelda Coleman
Psychiatric/Mental Health · San Diego, CANPI 1023345204
Payments from drug & device makers
Across 321 payments — averaging $20.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Otsuka America Pharmaceutical, Inc.$2K
- Neurocrine Biosciences, Inc.$2K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$2K
- AbbVie$1K
- Axsome Therapeutics, Inc.$197
- Teva Pharmaceuticals USA, Inc.$124
- plus $415 from 9 others
What the payments were for
- Food & beverage$6,599100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 86 | $1,702 |
| Neurocrine Biosciences, Inc. | 76 | $1,634 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 76 | $1,508 |
| AbbVie | 54 | $1,018 |
| Axsome Therapeutics, Inc. | 2 | $197 |
| Teva Pharmaceuticals USA, Inc. | 7 | $124 |
| Vanda Pharmaceuticals Inc. | 1 | $123 |
| Sunovion Pharmaceuticals Inc. | 6 | $73 |
| Lundbeck LLC | 3 | $56 |
| Johnson & Johnson | 3 | $56 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $40 |
| Corium, LLC | 1 | $22 |
| Alkermes, Inc. | 1 | $16 |
| Merck | 1 | $15 |
| Idorsia Pharmaceuticals US Inc | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- INGREZZA$602
- ABILIFY MAINTENA$246
- CAPLYTA$224
- Fanapt$123
- ABILIFY ASIMTUFII$123
- SUNOSI$118
How this compares
$6,599 in reported general payments places this provider in the 90th percentile of 2,433 psychiatric/mental health providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 22 | $178,852 |
| Lurasidone Hcl | 18 | $13,053 |
| Aripiprazole | 64 | $1,654 |
| Lamotrigine | 98 | $1,632 |
| Buspirone Hcl | 60 | $1,090 |
| Duloxetine Hcl | 44 | $806 |
| Hydroxyzine Hcl | 11 | $749 |
| Bupropion XlBupropion Hcl | 47 | $718 |
| Trazodone Hcl | 97 | $716 |
| Hydroxyzine Pamoate | 27 | $684 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 11 | $559 |
| Quetiapine Fumarate | 34 | $405 |
| Prazosin Hcl | 24 | $348 |
| Mirtazapine | 22 | $320 |
| Escitalopram Oxalate | 52 | $299 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Neurocrine Biosciences, Inc.Ingrezza | $1,634 | $178,85222 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,433 psychiatric/mental health providers in California.
Other psychiatric/mental health in San Diego
- Kelvin PoonSan Diego$16K
- Fernando SerranoSan Diego$16K
- Carey MartinMillbrae$745K
- Liberty MaciasRedlands$288K
- Joshua BurgettSacramento$239K
- Jovita Ezirim-SalamialofojeLos Angeles$162K
- Angie-Kolleen TanThousand Oaks$159K
- Thy LamVista$121K
- David OhIrvine$72K
- Samantha PerkinsAnaheim$49K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.